The company also announced new findings from an integrated analysis of the Phase 2 PAISLEY-SLE and PAISLEY long-term extension/LTE studies. The results showed sustained safety and efficacy with up to ...

Early childhood stress, especially before age 1, significantly increases psoriasis risk, with an odds ratio of 4.19. The study involved over 16,000 children, using data from the All Babies in ...

Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin health ZORYVE® (roflumilast) is the #1 prescribed branded ...

Learn more about whether Alvotech or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Arcutis Biotherapeutics surged as Q3 earnings beat forecasts and Zoryve sales boomed. Click for my updated look at ARQT stock ...

Shares in Arcutis Biotherapeutics (NASDAQ: ARQT) soared by almost 30% in trading to 10:30 a.m. ET today. The move comes after ...

Subgroup analyses from one of the agent's pivotal trials showed that 29.5% of adolescents receiving icotrokinra achieved PASI ...

In the VALOR trial, brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared ...

Prescription drug ads were once banned on broadcasts. But companies argued that infringed on free speech, and the drugs could ...